On the basis of these results, we reasoned that GnRH agonists, through Bax upregulation, might promote a perturbation in the balance between pro- and antiapoptotic factors, thus sensitizing prostate cancer cells to the activity of cytotoxic drugs, such as docetaxel. Here, BAX is linked to prostate carcinoma.